DUBLIN, Aug. 06, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/z2rjsb/investigation) has announced the addition of the "Investigation Report on China's Ezetimibe Market, 2010-2019" report to their offering.
With the sustained economic development and the improvements in diet, the Chinese people's blood fat level rises too. Many local epidemiological studies on blood fat have proved that a conservative estimate of the incidence of hyperlipemia is 7%-8% while the actual incidence might be above 10%. Over 100 million people in China have to receive cholesterol-lowering therapy, more so with the ageing society. As people increasingly pay attention to health, cholesterol-lowering drugs will become more and more promising.
The annual market size of statin drugs is estimated to surpass USD 20 billion around the world, growing at an annual rate of 20%.
Ezetimibe, the first cholesterol absorption selective inhibitor in the world, was jointly developed by Merck and Schering-Plough and approved by FDA in 2002 as the first drug for regulating blood fat with completely innovative mechanism of action after statin. Ezetimibe can selectively inhibit cholesterol transporter in the small intestine, effectively reduce cholesterol absorption, lower plasma cholesterol level and decrease the amount of cholesterol normally available to liver cells. As an ideal partner of statin, ezetimibe can provide better control rates for LDL-C with good safety and tolerance than doubled statin dose or more potent statin.
Ezetimibe in the Chinese market is monopolized by Schering-Plough. Ezetimibe develops fast after entering China with annual sales rising from less than CNY 0.05 million in 2007 to CNY 20.67 million in 2014 and CAGR during this period reaching up to 137%.
Key Topics Covered:
1 Related Concepts of Ezetimibe
2 Market Profile of Ezetimibe in China
3 Survey on Sales Status of Ezetimibe in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Ezetimibe in China, 2010-2014
5 Survey on Dosage Forms of Ezetimibe in China, 2010-2014
6 Reference Price of Ezetimibe in Chinese Hospitals in 2014
7 Major Manufacturers of Ezetimibe in Chinese Market, 2010-2014
8 Market Outlook of Ezetimibe in China, 2015-2019
For more information visit http://www.researchandmarkets.com/research/z2rjsb/investigation
Media Contact: Laura Wood , +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets